Mark S Sulkowski1, Hugo E Vargas2, Adrian M Di Bisceglie3, Alexander Kuo4, K Rajender Reddy5, Joseph K Lim6, Giuseppe Morelli7, Jama M Darling8, Jordan J Feld9, Robert S Brown10, Lynn M Frazier11, Thomas G Stewart8, Michael W Fried8, David R Nelson7, Ira M Jacobson12. 1. Johns Hopkins University School of Medicine, Baltimore, Maryland. Electronic address: msulkowski@jhmi.edu. 2. Mayo Clinic-Arizona, Phoenix, Arizona. 3. Saint Louis University School of Medicine, St. Louis, Missouri. 4. University of California, San Diego, California. 5. University of Pennsylvania, Philadelphia, Pennsylvania. 6. Yale University School of Medicine, New Haven, Connecticut. 7. University of Florida School of Medicine, Gainesville, Florida. 8. University of North Carolina School of Medicine, Chapel Hill, North Carolina. 9. Toronto Western Hospital Liver Center, Toronto, Canada. 10. Columbia University, New York, New York. 11. Liver Wellness Center, Little Rock, Arkansas. 12. Mount Sinai Beth Israel, New York, New York.
Abstract
BACKGROUND & AIMS: The interferon-free regimen of simeprevir plus sofosbuvir was recommended by professional guidelines for certain patients with hepatitis C virus (HCV) genotype 1 infection based on the findings of a phase 2 trial. We aimed to evaluate the safety and efficacy of this regimen in clinical practice settings in North America. METHODS: We collected demographic, clinical, and virologic data, as well as reports of adverse outcomes, from sequential participants in HCV-TARGET--a prospective observational cohort study of patients undergoing HCV treatment in routine clinical care settings. From January through October 2014, there were 836 patients with HCV genotype 1 infection who began 12 weeks of treatment with simeprevir plus sofosbuvir (treatment duration of up to 16 weeks); 169 of these patients received ribavirin. Most patients were male (61%), Caucasian (76%), or black (13%); 59% had cirrhosis. Most patients had failed prior treatment with peginterferon and ribavirin without (46%) or with telaprevir or boceprevir (12%). The primary outcome was sustained virologic response (SVR), defined as the level of HCV RNA below quantification at least 64 days after the end of treatment (beginning of week 12 after treatment--a 2-week window). Logistic regression models with inverse probability weights were constructed to adjust for baseline covariates and potential selection bias. RESULTS: The overall SVR rate was 84% (675 of 802 patients, 95% confidence interval, 81%-87%). Model-adjusted estimates indicate patients with cirrhosis, prior decompensation, and previous protease inhibitor treatments were less likely to achieve an SVR. The addition of ribavirin had no detectable effects on SVR. The most common adverse events were fatigue, headache, nausea, rash, and insomnia. Serious adverse events and treatment discontinuation occurred in only 5% and 3% of participants, respectively. CONCLUSIONS: In a large prospective observational cohort study, a 12-week regimen of simeprevir plus sofosbuvir was associated with high rates of SVR and infrequent treatment discontinuation. ClinicalTrials.gov: NCT01474811.
BACKGROUND & AIMS: The interferon-free regimen of simeprevir plus sofosbuvir was recommended by professional guidelines for certain patients with hepatitis C virus (HCV) genotype 1 infection based on the findings of a phase 2 trial. We aimed to evaluate the safety and efficacy of this regimen in clinical practice settings in North America. METHODS: We collected demographic, clinical, and virologic data, as well as reports of adverse outcomes, from sequential participants in HCV-TARGET--a prospective observational cohort study of patients undergoing HCV treatment in routine clinical care settings. From January through October 2014, there were 836 patients with HCV genotype 1 infection who began 12 weeks of treatment with simeprevir plus sofosbuvir (treatment duration of up to 16 weeks); 169 of these patients received ribavirin. Most patients were male (61%), Caucasian (76%), or black (13%); 59% had cirrhosis. Most patients had failed prior treatment with peginterferon and ribavirin without (46%) or with telaprevir or boceprevir (12%). The primary outcome was sustained virologic response (SVR), defined as the level of HCV RNA below quantification at least 64 days after the end of treatment (beginning of week 12 after treatment--a 2-week window). Logistic regression models with inverse probability weights were constructed to adjust for baseline covariates and potential selection bias. RESULTS: The overall SVR rate was 84% (675 of 802 patients, 95% confidence interval, 81%-87%). Model-adjusted estimates indicate patients with cirrhosis, prior decompensation, and previous protease inhibitor treatments were less likely to achieve an SVR. The addition of ribavirin had no detectable effects on SVR. The most common adverse events were fatigue, headache, nausea, rash, and insomnia. Serious adverse events and treatment discontinuation occurred in only 5% and 3% of participants, respectively. CONCLUSIONS: In a large prospective observational cohort study, a 12-week regimen of simeprevir plus sofosbuvir was associated with high rates of SVR and infrequent treatment discontinuation. ClinicalTrials.gov: NCT01474811.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Lisa I Backus; Derek B Boothroyd; Barbara R Phillips; Pamela Belperio; James Halloran; Larry A Mole Journal: Clin Gastroenterol Hepatol Date: 2011-03-11 Impact factor: 11.382
Authors: Berkeley N Limketkai; Shruti H Mehta; Catherine G Sutcliffe; Yvonne M Higgins; Michael S Torbenson; Sherilyn C Brinkley; Richard D Moore; David L Thomas; Mark S Sulkowski Journal: JAMA Date: 2012-07-25 Impact factor: 56.272
Authors: Michael Manns; Patrick Marcellin; Fred Poordad; Evaldo Stanislau Affonso de Araujo; Maria Buti; Yves Horsmans; Ewa Janczewska; Federico Villamil; Jane Scott; Monika Peeters; Oliver Lenz; Sivi Ouwerkerk-Mahadevan; Guy De La Rosa; Ronald Kalmeijer; Rekha Sinha; Maria Beumont-Mauviel Journal: Lancet Date: 2014-06-04 Impact factor: 79.321
Authors: Ira M Jacobson; Gregory J Dore; Graham R Foster; Michael W Fried; Monica Radu; Vladimir V Rafalsky; Larysa Moroz; Antonio Craxi; Monika Peeters; Oliver Lenz; Sivi Ouwerkerk-Mahadevan; Guy De La Rosa; Ronald Kalmeijer; Jane Scott; Rekha Sinha; Maria Beumont-Mauviel Journal: Lancet Date: 2014-06-04 Impact factor: 79.321
Authors: Shruti H Mehta; Becky L Genberg; Jacquie Astemborski; Ravi Kavasery; Gregory D Kirk; David Vlahov; Steffanie A Strathdee; David L Thomas Journal: J Community Health Date: 2008-06
Authors: Stuart C Gordon; Andrew J Muir; Joseph K Lim; Brian Pearlman; Curtis K Argo; Ananthakrishnan Ramani; Benedict Maliakkal; Imtiaz Alam; Thomas G Stewart; Monika Vainorius; Joy Peter; David R Nelson; Michael W Fried; K Rajender Reddy Journal: J Hepatol Date: 2014-09-10 Impact factor: 25.083
Authors: Adriaan J van der Meer; Bart J Veldt; Jordan J Feld; Heiner Wedemeyer; Jean-François Dufour; Frank Lammert; Andres Duarte-Rojo; E Jenny Heathcote; Michael P Manns; Lorenz Kuske; Stefan Zeuzem; W Peter Hofmann; Robert J de Knegt; Bettina E Hansen; Harry L A Janssen Journal: JAMA Date: 2012-12-26 Impact factor: 56.272
Authors: Eric Lawitz; Mark S Sulkowski; Reem Ghalib; Maribel Rodriguez-Torres; Zobair M Younossi; Ana Corregidor; Edwin DeJesus; Brian Pearlman; Mordechai Rabinovitz; Norman Gitlin; Joseph K Lim; Paul J Pockros; John D Scott; Bart Fevery; Tom Lambrecht; Sivi Ouwerkerk-Mahadevan; Katleen Callewaert; William T Symonds; Gaston Picchio; Karen L Lindsay; Maria Beumont; Ira M Jacobson Journal: Lancet Date: 2014-07-28 Impact factor: 79.321
Authors: Joseph K Lim; Ann Marie Liapakis; Mitchell L Shiffman; Anna S Lok; Stefan Zeuzem; Norah A Terrault; James S Park; Charles S Landis; Mohamed Hassan; Joel Gallant; Alexander Kuo; Paul J Pockros; Monika Vainorius; Lucy Akushevich; Larry Michael; Michael W Fried; David R Nelson; Ziv Ben-Ari Journal: Clin Gastroenterol Hepatol Date: 2018-01-03 Impact factor: 11.382
Authors: Alex I Aspinall; Abdel A Shaheen; Golasa S Kochaksaraei; Breean Haslam; Samuel S Lee; Gisela Macphail; Jeff Kapler; Oscar E Larios; Kelly W Burak; Mark G Swain; Meredith A Borman; Carla S Coffin Journal: CMAJ Open Date: 2018-01-05
Authors: Varun Saxena; Vandana Khungar; Elizabeth C Verna; Josh Levitsky; Robert S Brown; Mohamed A Hassan; Mark S Sulkowski; Jacqueline G O'Leary; Farrukh Koraishy; Joseph S Galati; Alexander A Kuo; Monika Vainorius; Lucy Akushevich; David R Nelson; Michael W Fried; Norah Terrault; K Rajender Reddy Journal: Hepatology Date: 2017-09-04 Impact factor: 17.425
Authors: Jordan J Feld; Raoel Maan; Stefan Zeuzem; Alexander Kuo; David R Nelson; Adrian M Di Bisceglie; Michael P Manns; Ken Sherman; Lynn M Frazier; Richard Sterling; Mark Mailliard; Monica Schmidt; Lucy Akushevich; Monika Vainorius; Michael W Fried Journal: Clin Infect Dis Date: 2016-06-19 Impact factor: 9.079
Authors: Moisés Uriarte-Pinto; Herminia Navarro-Aznarez; Natalia De La Llama-Celis; Piedad Arazo-Garcés; Ana María Martínez-Sapiña; María Reyes Abad-Sazatornil Journal: Int J Clin Pharm Date: 2018-03-20
Authors: Norah A Terrault; Stefan Zeuzem; Adrian M Di Bisceglie; Joseph K Lim; Paul J Pockros; Lynn M Frazier; Alexander Kuo; Anna S Lok; Mitchell L Shiffman; Ziv Ben Ari; Lucy Akushevich; Monika Vainorius; Mark S Sulkowski; Michael W Fried; David R Nelson Journal: Gastroenterology Date: 2016-08-24 Impact factor: 22.682